Longitudinal Tumor Burden Quantification Using Circulating Tumor DNA in Metastatic Lobular Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this study is to characterize early dynamic changes in ctDNA, which can aid in tailoring early therapy in patients with metastatic Invasive lobular carcinoma (ILC). Response assessment using ctDNA analysis could not only aid in de-escalation but also escalation strategies.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podpisana świadoma zgoda
- •Potwierdzony histologicznie zrazikowy rak piersi z dodatnim receptorem estrogenowym i ujemnym HER2, z przerzutami
- •Dostępna tkanka guza do badania genetycznego
- •Brak wcześniejszego leczenia choroby przerzutowej (dozwolone leczenie uzupełniające)
- •Wiek od 18 lat
✗ Disqualifies
- •Rak piersi w stadium I-III
- •Brak potwierdzenia typu zrazikowego w biopsji
- •Inny aktywny nowotwór złośliwy
- •Niemożność wykonania badania genetycznego z powodu niewystarczającej tkanki
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 20, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Magee Women's Hospital of UPMC
Pittsburgh, United States
Trial contact
Lucia Borasso, BA
Kelsey Mitch, RN
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.